文献速递白血病淋巴瘤

组蛋白去乙酰化酶抑制剂givinostat(ITF2357)对CRLF2重排的B细胞前体急性淋巴细胞白血病表现出强效抗肿瘤活性

The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL.
PubMed 文献 · Leukemia · 2017-03-23

本研究探讨组蛋白去乙酰化酶抑制剂givinostat对CRLF2重排的B细胞前体急性淋巴细胞白血病(BCP-ALL)的作用。体外实验显示givinostat抑制细胞增殖、诱导凋亡,下调JAK/STAT通路基因并抑制STAT5磷酸化;体内实验显著减少患者来源异种移植模型中人白血病细胞的植入。givinostat可杀伤鲁索替尼耐药细胞并增强化疗效果,作者认为其联合常规化疗可能成为有效治疗选择。

要点

  • givinostat抑制CRLF2重排BCP-ALL细胞系增殖并诱导凋亡,对携带CRLF2重排的患者原代细胞有杀伤作用而不影响正常造血细胞。
  • 低剂量givinostat下调JAK/STAT通路基因表达并抑制STAT5磷酸化。
  • givinostat在体内显著减少CRLF2阳性BCP-ALL患者来源异种移植模型中人白血病细胞的植入。

核心结论

  • givinostat可杀伤鲁索替尼耐药细胞并增强现有化疗的效果,作者认为givinostat联合常规化疗可能代表此类难治性ALL亚群的有效治疗选择。
  • givinostat对癌细胞的选择性杀伤可能允许为CRLF2重排的唐氏综合征相关BCP-ALL患者设计降低强度的方案,从而在毒性和相关并发症方面获得总体获益。

研究设计与样本

  • 研究采用BCP-ALL CRLF2重排细胞系(携带JAK2外显子16突变)、携带CRLF2重排的患者原代细胞及其正常造血对应细胞进行体外实验,并在CRLF2阳性BCP-ALL患者来源异种移植模型中进行体内实验。

主要发现

  • givinostat抑制BCP-ALL CRLF2重排细胞系的增殖并诱导凋亡,这些细胞系为JAK2外显子16突变阳性。
  • givinostat杀伤携带CRLF2重排的患者原代细胞,但不杀伤其正常造血对应细胞。
  • 低剂量givinostat下调JAK/STAT通路基因的表达并抑制STAT5磷酸化。
  • 在体内,givinostat显著减少CRLF2阳性BCP-ALL患者来源异种移植模型中人白血病细胞的植入。
  • givinostat杀伤鲁索替尼耐药细胞并增强当前化疗的效果。

临床怎么用

  • 作者认为givinostat联合常规化疗可能代表此类难治性ALL亚群的有效治疗选择。
  • 作者提出givinostat对癌细胞的选择性杀伤可能允许为CRLF2重排的唐氏综合征相关BCP-ALL患者设计降低强度的方案,从而在毒性和相关并发症方面获得总体获益。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Leukemias bearing CRLF2 and JAK2 gene alterations are characterized by aberrant JAK/STAT signaling and poor prognosis. The HDAC inhibitor givinostat/ITF2357 has been shown to exert anti-neoplastic activity against both systemic juvenile idiopathic arthritis and myeloproliferative neoplasms through inhibition of the JAK/STAT pathway. These findings led us to hypothesize that givinostat might also act against CRLF2-rearranged BCP-ALL, which lack effective therapies. Here, we found that givinostat inhibited proliferation and induced apoptosis of BCP-ALL CRLF2-rearranged cell lines, positive for exon 16 JAK2 mutations. Likewise, givinostat killed primary cells, but not their normal hematopoietic counterparts, from patients carrying CRLF2 rearrangements. At low doses, givinostat downregulated the expression of genes belonging to the JAK/STAT pathway and inhibited STAT5 phosphorylation. In vivo, givinostat significantly reduced engraftment of human blasts in patient-derived xenograft models of CRLF2-positive BCP-ALL. Importantly, givinostat killed ruxolitinib-resistant cells and potentiated the effect of current chemotherapy. Thus, givinostat in combination with conventional chemotherapy may represent an effective therapeutic option for these difficult-to-treat subsets of ALL. Lastly, the selective killing of cancer cells by givinostat may allow the design of reduced intensity regimens in CRLF2-rearranged Down syndrome-associated BCP-ALL patients with an overall benefit in terms of both toxicity and related complications.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Savino AM, Sarno J, Trentin L, et al. The histone deacetylase inhibitor givinostat (ITF2357) exhibits potent anti-tumor activity against CRLF2-rearranged BCP-ALL. Leukemia. 2017. PMID: 28331226. doi:10.1038/leu.2017.93

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。